X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
VENUS REMEDIES LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

VENUS REMEDIES LIMITED  (VSRM)


Here is the latest financial fact sheet of VENUS REMEDIES. For more details, see the VENUS REMEDIES quarterly results and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
venus remedies - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 98.5       No. of shares m 11.44
    Mkt Cap Rs m 1,127       % ch % -0.5
    Vol '000 10.2       % ch week % -2.5
    P/E X -880.3       % ch 1-mth % -3.8
    P/CF X 2.6       % ch 12-mth % 10.0
    EPS (TTM) Rs -0.1       52 week H/L Rs 142.8/65.0
(As on Mar 24, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs276328358330218 
Low Rs14115814010382 
Sales per share (Unadj.) Rs420.8444.6473.4405.6365.6 
Earnings per share (Unadj.) Rs48.354.456.24.51.5 
Diluted earnings per shareRs41.150.156.24.51.5 
Cash flow per share (Unadj.) Rs74.285.891.444.737.9 
Dividends per share (Unadj.) Rs3.003.00000 
Adj. dividends per shareRs2.552.760.000.000.00 
Dividend yield (eoy) %1.41.2000 
Book value per share (Unadj.) Rs315.5359.7403.5399.2382.5 
Adj. book value per shareRs268.6331.4403.5399.2382.5 
Shares outstanding (eoy) m9.7410.5411.4411.4411.44 
Bonus/Rights/Conversions  WCWCWC-- 
Price / Sales ratio x0.50.50.50.50.4 
Avg P/E ratio x4.34.54.447.9101.0 
P/CF ratio (eoy) x2.82.82.74.84.0 
Price / Book Value ratio x0.70.70.60.50.4 
Dividend payout %6.25.5000 
Avg Mkt Cap Rs m2,0312,5602,8492,4711,717 
No. of employees `000NANANANA1.0 
Total wages/salary Rs m248273305324324 
Avg. sales/employee Rs ThNMNMNMNM4,100.7 
Avg. wages/employee Rs ThNMNMNMNM318.0 
Avg. net profit/employee Rs ThNMNMNMNM16.7 
  INCOME DATA
Net Sales Rs m4,0984,6865,4164,6404,183 
Other income Rs m545720 
Total revenues Rs m4,1034,6915,4204,6474,203 
Gross profit Rs m1,0311,2011,382892812 
Depreciation Rs m252331402460417 
Interest Rs m275246294412380 
Profit before tax Rs m5096286912735 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m385548-2518 
Profit after tax Rs m4715736435217 
Gross profit margin %25.225.625.519.219.4 
Effective tax rate %7.48.86.9-94.851.6 
Net profit margin %11.512.211.91.10.4 
  BALANCE SHEET DATA
Current assets Rs m1,6962,2562,7212,6752,771 
Current liabilities Rs m1,5321,9132,1101,9651,931 
Net working cap to sales %4.07.311.315.320.1 
Current ratio x1.11.21.31.41.4 
Inventory Days Days8610096112125 
Debtors Days Days3637445054 
Net fixed assets Rs m2,0544,0565,0735,2195,328 
Share capital Rs m97105114114114 
"Free" reserves Rs m2,0782,6064,4504,4454,177 
Net worth Rs m3,0733,7914,6164,5674,376 
Long term debt Rs m9911,2911,4001,6861,911 
Total assets Rs m5,7407,1768,3448,4118,428 
Interest coverage x2.83.63.31.11.1 
Debt to equity ratio x0.30.30.30.40.4 
Sales to assets ratio x0.70.70.60.60.5 
Return on assets %13.011.411.25.54.7 
Return on equity %15.315.113.91.10.4 
Return on capital %19.317.216.47.06.6 
Exports to sales %00000 
Imports to sales %13.214.817.017.720.5 
Exports (fob) Rs m00000 
Imports (cif) Rs m542695921821858 
Fx inflow Rs m00000 
Fx outflow Rs m00921822858 
Net fx Rs m00-921-822-858 
  CASH FLOW
From Operations Rs m 417 522 527 678 469 
From Investments Rs m -952 -1,039 -947 -672 29 
From Financial Activity Rs m 533 552 401 -14 -464 
Net Cashflow Rs m -2 34 -20 -8 35 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for venus remedies limited

 Share Holding
Indian Promoters : 32.9%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 0.2%
FIIs : 0.6%
ADR/GDR : 0.0%
Free float : 66.4%
Shareholders : 20,121
Pledged promoter(s) holding : 36.4%
 Company Information
Top
    REGD OFF: SCO 857, 2nd Floor, Cabin No. 10, NAC Manimajra, Chandigarh-160 101
    E-MAIL: investorgrievance@venusremedies.com     WEB: www.venusremedies.com
    TELEPHONE: (0172) 393 3094     FAX: (0172) 256 5566
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, A-31, Naraina Indl. Area, Phase 1, New Delhi-28
    AUDITOR: J. K. Jain & Assoc.
CHM: Pawan Chaudhary (MD) COMP SEC: Neha Kodan YEAR OF INC: 1989 BSE CODE: 526953 FV (Rs): 10 DIV YIELD (%): -

More pharmaceuticals Company Fact Sheets:   WYETH LTDTORRENT PHARMAPANACEA BIOTECHALKEM LABORATORIESSUVEN LIFE


Today's Market

Sensex Finishes Marginally Higher; Jaitley's Comments Boost Bank Stocks(Closing)

Indian share markets trimmed their early gains in the afternoon session to finish marginally higher. At the closing bell, the BSE Sensex stood higher by 89 points, while the NSE Nifty finished up by 22 points.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

As Digital Transactions Fall, Indians Are Going Back to Cash(Vivek Kaul's Diary)

Mar 16, 2017

Digital transactions have fallen since December 2016 both in value and volume terms.

Doubled Your Money In D-Mart? Read This Before It's Too Late(Daily Profit Hunter)

Mar 22, 2017

Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.

Stock Markets and Gold Rally, Dollar Tumbles(Chart Of The Day)

Mar 16, 2017

Markets are moving up even after the fed interest rate hike.

4 Things To Watch Out For After Modi's Landslide Win In UP Polls(Outside View)

Mar 15, 2017

PersonalFN explains why you need to wary while investing in equities despite Modi's UP win.

More

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ORCHID PHARMA LTD COMPARISON

Compare Company With Charts

COMPARE VENUS REMEDIES WITH

MARKET STATS